Immunoregulation by mesenchymal stem cells: Biological aspects and clinical applications

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Castro Manrreza, Marta E ^a   Montesinos, Juan J ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN; HLA G ANTIGEN; HLA G5 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

B LYMPHOCYTE; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CYTOLOGY; HEMATOPOIESIS; IMMUNOLOGY; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL;

AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HUMANS; IMMUNOMODULATION; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES;

EID: 84929353372     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/394917     Document Type: Review

References (166)

1. D. G. Phinney and D. J. Prockop, "Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views, " Stem Cells, vol. 25, no. 11, pp. 2896-2902, 2007.
2. S. Ma, N. Xie, W. Li, B. Yuan, Y. Shi, and Y. Wang, "Immunobiology of mesenchymal stem cells, " Cell Death and Differentiation, vol. 21, no. 2, pp. 216-225, 2014.
3. D. J. Prockop and J. Youn Oh, "Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation, "MolecularTherapy, vol. 20, no. 1, pp. 14-20, 2012.
4. A. J. Friedenstein, U. F. Deriglasova, N. N. Kulagina et al., "Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method, " Experimental Hematology, vol. 2, no. 2, pp. 83-92, 1974.
5. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells, " Science, vol. 284, no. 5411, pp. 143-147, 1999.
6. M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for CellularTherapy position statement, " Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
7. B. M. Seo, M. Miura, S. Gronthos et al., "Investigation of multipotent postnatal stem cells from human periodontal ligament, " The Lancet, vol. 364, no. 9429, pp. 149-155, 2004.
8. M. Najar, G. Raicevic, H. I. Boufker et al., "Mesenchymal stromal cells use PGE2 tomodulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources, " Cellular Immunology, vol. 264, no. 2, pp. 171-179, 2010.
9. J. J. Montesinos, E. Flores-Figueroa, S. Castillo-Medina et al., "Human mesenchymal stromal cells from adult and neonatal sources: Comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression, " Cytotherapy, vol. 11, no. 2, pp. 163-176, 2009.
10. J. J. Montesinos, M. D. L. Mora-Garcá, H. Mayani et al., "In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity, " Stem Cells and Development, vol. 22, no. 18, pp. 2508-2519, 2013.
11. E. M. Horwitz, P. L. Gordon, W. K. K. Koo et al., "Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 8932-8937, 2002.
12. S.-L. Chen, W.-W. Fang, F. Ye et al., "Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction, " American Journal of Cardiology, vol. 94, no. 1, pp. 92-95, 2004.
13. R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Daübener, and D. Dilloo, "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenasemediated tryptophan degradation, " Blood, vol. 103, no. 12, pp. 4619-4621, 2004.
14. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses, " Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
15. X.-X. Jiang, Y. Zhang, B. Liu et al., "Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells, " Blood, vol. 105, no. 10, pp. 4120-4126, 2005.
16. M. Krampera, L. Cosmi, R. Angeli et al., "Role for interferon-in the immunomodulatory activity of human bone marrow mesenchymal stem cells, " Stem Cells, vol. 24, no. 2, pp. 386-398, 2006.
17. J. M. Ryan, F. Barry, J. M. Murphy, andB. P. Mahon, "Interferon-does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells, " Clinical & Experimental Immunology, vol. 149, no. 2, pp. 353-363, 2007.
18. M. Wang, D. Windgassen, and E. T. Papoutsakis, "Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation, " BMC Genomics, vol. 9, article 225, 2008.
19. K. le Blanc, I. Rasmusson, C. Götherström et al., "Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes, " Scandinavian Journal of Immunology, vol. 60, no. 3, pp. 307-315, 2004.
20. M. E. Groh, B. Maitra, E. Szekely, and O. N. Koç, "Human mesenchymal stem cells requiremonocyte-mediated activation to suppress alloreactive T cells, " Experimental Hematology, vol. 33, no. 8, pp. 928-934, 2005.
21. R. Ramasamy, C. K. Tong, H. F. Seow, S. Vidyadaran, and F. Dazzi, "The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function, " Cellular Immunology, vol. 251, no. 2, pp. 131-136, 2008.
22. F. Saldanha-Araujo, R. Haddad, K. C. R. M. de Farias et al., "Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and noncanonical NF-B signalling, " Journal of Cellular and Molecular Medicine, vol. 16, no. 6, pp. 1232-1244, 2012.
23. B. Kronsteiner, S. Wolbank, A. Peterbauer et al., "Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells, " Stem Cells and Development, vol. 20, no. 12, pp. 2115-2126, 2011.
24. M. E. Castro-Manrreza, H. Mayani, A. Monroy-Garcá et al., "Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against t cells, " Stem Cells and Development, vol. 23, no. 11, pp. 1217-1232, 2014.
25. W.-T. Hsu, C.-H. Lin, B.-L. Chiang, H.-Y. Jui, K. K.-Y. Wu, and C.-M. Lee, "Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-+CD4+ regulatory T cells to control transplant arteriosclerosis, "The Journal of Immunology, vol. 190, no. 5, pp. 2372-2380, 2013.
26. S. Beyth, Z. Borovsky, D. Mevorach et al., "Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness, " Blood, vol. 105, no. 5, pp. 2214-2219, 2005.
27. P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, "Interactions between human mesenchymal stem cells and natural killer cells, " Stem Cells, vol. 24, no. 1, pp. 74-85, 2006.
28. Z. Selmani, A. Naji, and I. Zidi, "Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte andnatural killer functionand to induce CD4+CD25 highFOXP3+ regulatory T cells, " Stem Cells, vol. 26, no. 1, pp. 212-222, 2008.
29. H. Sheng, Y. Wang, Y. Jin et al., "A critical role of IFNin priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1, " Cell Research, vol. 18, no. 8, pp. 846-857, 2008.
30. M. Giuliani, M. Fleury, A. Vernochet et al., "Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on Tlymphocyte proliferation, " PLoS ONE, vol. 6, no. 5, Article ID e19988, 2011.
31. M. D. Nicola, C. Carlo-Stella, M. Magni et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, " Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
32. I. Rasmusson, O. Ringdén, B. Sundberg, and K. Le Blanc, "Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms, " Experimental Cell Research, vol. 305, no. 1, pp. 33-41, 2005.
33. G. Xu, L. Zhang, G. Ren et al., "Immunosuppressive properties of cloned bone marrow mesenchymal stem cells, " Cell Research, vol. 17, no. 3, pp. 240-248, 2007.
34. S. Tipnis, C. Viswanathan, and A. S. Majumdar, "Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO, " Immunology and Cell Biology, vol. 88, no. 8, pp. 795-806, 2010.
35. S. Ghannam, J. Pène, G. Torcy-Moquet, C. Jorgensen, and H. Yssel, "Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype, " Journal of Immunology, vol. 185, no. 1, pp. 302-312, 2010.
36. P. Luz-Crawford, M. Kurte, J. Bravo-Alegrá et al., "Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells, " Stem Cell Research and Therapy, vol. 4, no. 3, article 65, 2013.
37. R. Maccario, M. Podestà, A. Moretta et al., "Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype, " Haematologica, vol. 90, no. 4, pp. 516-525, 2005.
38. C. Prevosto, M. Zancolli, P. Canevali, M. R. Zocchi, and A. Poggi, "Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction, " Haematologica, vol. 92, no. 7, pp. 881-888, 2007.
39. K. English, J. M. Ryan, L. Tobin, M. J. Murphy, F. P. Barry, and B. P. Mahon, "Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells, " Clinical & Experimental Immunology, vol. 156, no. 1, pp. 149-160, 2009.
40. M. di Ianni, B. del Papa, M. de Ioanni et al., "Mesenchymal cells recruit and regulate T regulatory cells, " Experimental Hematology, vol. 36, no. 3, pp. 309-318, 2008.
41. H. Y. Jui, C. H. Lin, W. T. Hsu et al., "Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-, and indoleamine 2, 3-dioxygenase, " Cell Transplantation, vol. 21, no. 5, pp. 971-984, 2012.
42. R. Jitschin, D. Mougiakakos, L. von Bahr et al., "Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation, " Stem Cells, vol. 31, no. 8, pp. 1715-1725, 2013.
43. F. Carrion, E. Nova, C. Ruiz et al., "Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients, " Lupus, vol. 19, no. 3, pp. 317-322, 2010.
44. N. Perico, F. Casiraghi, M. Introna et al., "Autologousmesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility, " Clinical Journal of the American Society of Nephrology, vol. 6, no. 2, pp. 412-422, 2011.
45. Y.-J. Liu, H. Kanzler, V. Soumelis, andM. Gilliet, "Dendritic cell lineage, plasticity and cross-regulation, " Nature Immunology, vol. 2, no. 7, pp. 585-589, 2001.
46. A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, and W. E. Fibbe, "Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells, " The Journal of Immunology, vol. 177, no. 4, pp. 2080-2087, 2006.
47. G. M. Spaggiari, H. Abdelrazik, F. Becchetti, and L. Moretta, "MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2, " Blood, vol. 113, no. 26, pp. 6576-6583, 2009.
48. W. Zhang, W. Ge, C. Li et al., "Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells, " Stem Cells and Development, vol. 13, no. 3, pp. 263-271, 2004.
49. Y.-P. Li, S. Paczesny, E. Lauret et al., "Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway, "The Journal of Immunology, vol. 180, no. 3, pp. 1598-1608, 2008.
50. T. Walzer, M. Dalod, S. H. Robbins, L. Zitvogel, and E. Vivier, "Natural-killer cells and dendritic cells: "l'union fait la force", " Blood, vol. 106, no. 7, pp. 2252-2258, 2005.
51. G. Maria Spaggiari and L. Moretta, "Cellular and molecular interactions of mesenchymal stem cells in innate immunity, " Immunology and Cell Biology, vol. 91, no. 1, pp. 27-31, 2013.
52. M. Franquesa, M. J. Hoogduijn, O. Bestard, and J. M. Grinyó, "Immunomodulatory effect of mesenchymal stem cells on B cells, " Frontiers in Immunology, vol. 3, article 212, 2012.
53. A. Corcione, F. Benvenuto, E. Ferretti et al., "Humanmesenchymal stem cells modulate B-cell functions, " Blood, vol. 107, no. 1, pp. 367-372, 2006.
54. M. M. Rosado, M. E. Bernardo, M. Scarsella et al., "Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells, " Stem Cells and Development, 2014.
55. S. Tabera, J. A. Pérez-Simón, M. Déz-Campelo et al., "The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes, " Haematologica, vol. 93, no. 9, pp. 1301-1309, 2008.
56. P. Comoli, F. Ginevri, R. MacCario et al., "Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation, " Nephrology Dialysis Transplantation, vol. 23, no. 4, pp. 1196-1202, 2008.
57. D. H. Munn andA. L. Mellor, "Indoleamine 2, 3 dioxygenase and metabolic control of immune responses, " Trends in Immunology, vol. 34, no. 3, pp. 137-143, 2013.
58. P. Kalinski, "Regulation of immune responses by prostaglandin E2, "The Journal of Immunology, vol. 188, no. 1, pp. 21-28, 2012.
59. F. Baratelli, Y. Lin, L. Zhu et al., "Prostaglandin E2 induces FOXP3 gene expression andTregulatory cell function in human CD4+ T cells, " The Journal of Immunology, vol. 175, no. 3, pp. 1483-1490, 2005.
60. M. A. Avanzini, M. E. Bernardo, A. M. Cometa et al., "Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood-and bone marrow-derived progenitors, " Haematologica, vol. 94, no. 12, pp. 1649-1660, 2009.
61. W.-H. Liu, J.-J. Liu, J. Wu et al., "Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway, " PLoS ONE, vol. 8, no. 1, Article ID e55487, 2013.
62. S. L. Tomchuck, K. J. Zwezdaryk, S. B. Coffelt, R. S. Waterman, E. S. Danka, and A. B. Scandurro, "Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses, " Stem Cells, vol. 26, no. 1, pp. 99-107, 2008.
63. K. English, F. P. Barry, C. P. Field-Corbett, and B. P. Mahon, "IFN-and TNF-differentially regulate immunomodulation by murine mesenchymal stem cells, " Immunology Letters, vol. 110, no. 2, pp. 91-100, 2007.
64. M. Najar, G. Raicevic, H. Fayyad-Kazan et al., "Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the t cell response: the importance of the IL-10/CD210 axis, " Stem Cell Reviews and Reports, 2014.
65. Z. Yan, Y. Zhuansun, R. Chen, J. Li, and P. Ran, "Immunomodulation ofmesenchymal stromal cells on regulatory T cells and its possible mechanism, " Experimental Cell Research, vol. 324, no. 1, pp. 65-74, 2014.
66. E. D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. Lemaoult, "Beyond the increasing complexity of the immunomodulatory HLA-G molecule, " Blood, vol. 111, no. 10, pp. 4862-4870, 2008.
67. R. Rizzo, D. Campioni, M. Stignani et al., "A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells, " Cytotherapy, vol. 10, no. 4, pp. 364-375, 2008.
68. V. L. J. L. Thijssen, F. Poirier, L. G. Baum, and A. W. Griffioen, "Galectins in the tumor endothelium: opportunities for combined cancer therapy, " Blood, vol. 110, no. 8, pp. 2819-2827, 2007.
69. T. Kadri, J.-J. Lataillade, C. Doucet et al., "Proteomic study of galectin-1 expression in human mesenchymal stem cells, " Stem Cells and Development, vol. 14, no. 2, pp. 204-212, 2005.
70. F. Gieseke, J. Böhringer, R. Bussolari, M. Dominici, R. Handgretinger, and I. Müller, "Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells, " Blood, vol. 116, no. 19, pp. 3770-3779, 2010.
71. Y. Lepelletier, S. Lecourt, A. Renand et al., "Galectin-1 and semaphorin-3A are two soluble factors conferring t-cell immunosuppression to bone marrow mesenchymal stem cell, " Stem Cells and Development, vol. 19, no. 7, pp. 1075-1079, 2010.
72. M. Sioud, A. Mobergslien, A. Boudabous, and Y. Fløisand, "Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation, " Scandinavian Journal of Immunology, vol. 71, no. 4, pp. 267-274, 2010.
73. C. Ungerer, P. Quade-Lyssy, H. H. Radeke et al., "Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations, " Stem Cells and Development, vol. 23, no. 7, pp. 755-766, 2014.
74. F. Gieseke, A. Kruchen, N. Tzaribachev, F. Bentzien, M. Dominici, and I. Müller, "Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress Tcell proliferation, " European Journal of Immunology, vol. 43, no. 10, pp. 2741-2749, 2013.
75. L. M. Francisco, P. T. Sage, and A. H. Sharpe, "ThePD-1 pathway in tolerance and autoimmunity, " Immunological Reviews, vol. 236, no. 1, pp. 219-242, 2010.
76. C.-J. Chang, M.-L. Yen, Y.-C. Chen et al., "Placenta-derived multipotent cells exhibitimmunosuppressive properties that are enhanced in the presence of interferon-, " StemCells, vol. 24, no. 11, pp. 2466-2477, 2006.
77. Z. Yan, Y. Zhuansun, G. Liu, R. Chen, J. Li, and P. Ran, "Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions, " Immunology Letters, vol. 162, no. 1, pp. 248-255, 2014.
78. G. Ren, X. Zhao, L. Zhang et al., "Inflammatory cytokineinduced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression, " The Journal of Immunology, vol. 184, no. 5, pp. 2321-2328, 2010.
79. N. K. Damle, K. Klussman, G. Leytze et al., "Costimulation of T lymphocytes with Lntegrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7, " The Journal of Immunology, vol. 152, no. 6, pp. 2686-2697, 1994.
80. L. Gatta, G. Calviello, F. Di Nicuolo et al., "Cytotoxic T lymphocyte-associated antigen-4 inhibits integrin-mediated stimulation, " Immunology, vol. 107, no. 2, pp. 209-216, 2002.
81. S. Selleri, M. M. Dieng, S. Nicoletti et al., "Cord-bloodderivedmesenchymal stromal cells downmodulate CD4+ T-cell activation by inducing il-10-producing th1 cells, " Stem Cells and Development, vol. 22, no. 7, pp. 1063-1075, 2013.
82. L. Chen and D. B. Flies, "Molecular mechanisms of T cell costimulation and co-inhibition, " Nature Reviews Immunology, vol. 13, no. 4, pp. 227-242, 2013.
83. T. N. Eagar, Q. Tang, M. Wolfe, Y. He, W. S. Pear, and J. A. Bluestone, "Notch 1 signaling regulates peripheral T cell activation, " Immunity, vol. 20, no. 4, pp. 407-415, 2004.
84. F. Liotta, R. Angeli, L. Cosmi et al., "Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling, " Stem Cells, vol. 26, no. 1, pp. 279-289, 2008.
85. X. Han, Q. Yang, L. Lin et al., "Interleukin-17 enhances immunosuppression by mesenchymal stem cells, " Cell Death & Differentiation, vol. 21, no. 11, pp. 1758-1768, 2014.
86. J. A. Ankrum, J. F. Ong, and J. M. Karp, "Mesenchymal stem cells: immune evasive, not immune privileged, " Nature Biotechnology, vol. 32, no. 3, pp. 252-260, 2014.
87. J. Cuerquis, R. Romieu-Mourez, M. François et al., "Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-and tumor necrosis factor-stimulation, " Cytotherapy, vol. 16, no. 2, pp. 191-202, 2014.
88. D. Polchert, J. Sobinsky, G. W. Douglas et al., "IFN-activation of mesenchymal stem cells for treatment and prevention of graft versus host disease, " European Journal of Immunology, vol. 38, no. 6, pp. 1745-1755, 2008.
89. O. Ringdén, M. Uzunel, I. Rasmusson et al., "Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease, " Transplantation, vol. 81, no. 10, pp. 1390-1397, 2006.
90. K. Le Blanc, F. Frassoni, L. Ball et al., "Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: a phase II study, " The Lancet, vol. 371, no. 9624, pp. 1579-1586, 2008.
91. H. Ning, F. Yang, M. Jiang et al., "The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study, " Leukemia, vol. 22, no. 3, pp. 593-599, 2008.
92. B. Beutler, "Inferences, questions and possibilities in Toll-like receptor signalling, " Nature, vol. 430, no. 6996, pp. 257-263, 2004.
93. D. N. Cook, D. S. Pisetsky, andD. A. Schwartz, "Toll-like receptors in the pathogenesis of human disease, " Nature Immunology, vol. 5, no. 10, pp. 975-979, 2004.
94. C. A. Opitz, U. M. Litzenburger, C. Lutz et al., "Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-and protein kinase R, " Stem Cells, vol. 27, no. 4, pp. 909-919, 2009.
95. R. S. Waterman, S. L. Tomchuck, S. L. Henkle, and A. M. Betancourt, "A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype, " PLoS ONE, vol. 5, no. 4, Article ID e10088, 2010.
96. M. Giuliani, A. Bennaceur-Griscelli, A. Nanbakhsh et al., "TLR ligands stimulation protects MSC from NK killing, " Stem Cells, vol. 32, no. 1, pp. 290-300, 2014.
97. B. J. Jones, G. Brooke, K. Atkinson, and S. J. McTaggart, "Immunosuppression by placental indoleamine 2, 3-dioxygenase: a role for mesenchymal stem cells, " Placenta, vol. 28, no. 11-12, pp. 1174-1181, 2007.
98. M. Stubbendorff, T. Deuse, X. Hua et al., "Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue, " Stem Cells and Development, vol. 22, no. 19, pp. 2619-2629, 2013.
99. X. Li, J. Bai, X. Ji et al., "Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation, " International Journal Molecular Medicine, vol. 34, no. 4, pp. 695-704, 2014.
100. K. Chen, D. Wang, W. T. Du et al., "Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism, " Clinical Immunology, vol. 135, no. 3, pp. 448-458, 2010.
101. K. H. Yoo, I. K. Jang, M. W. Lee et al., "Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues, " Cellular Immunology, vol. 259, no. 2, pp. 150-156, 2009.
102. A. Ribeiro, P. Laranjeira, S. Mendes et al., "Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrowexhibit different capability to suppress peripheral blood B, natural killer and T cells, " Stem Cell Research & Therapy, vol. 4, no. 5, article 125, 2013.
103. M. Roemeling-van Rhijn, M. Khairoun, S. S. Korevaar et al., "Human bone marrow-and adipose tissue-derived mesenchymal stromal cells are immunosuppressive in vitro and in a humanized allograft rejection model, " Journal of Stem Cell Research & Therapy, supplement 6, article 1, Article ID 20780, 2013.
104. S. J. Prasanna, D. Gopalakrishnan, S. R. Shankar, and A. B. Vasandan, "Pro-inflammatory cytokines, IFNand TNF, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially, " PLoS ONE, vol. 5, no. 2, Article ID e9016, 2010.
105. C. D. Li, W. Y. Zhang, H. L. Li et al., "Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation, " Cell Research, vol. 15, no. 7, pp. 539-547, 2005.
106. P. Niemeyer, M. Kornacker, A. Mehlhorn et al., "Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro, " Tissue Engineering, vol. 13, no. 1, pp. 111-121, 2007.
107. H. Fazekasova, R. Lechler, K. Langford, and G. Lombardi, "Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs, " Journal of Tissue Engineering and Regenerative Medicine, vol. 5, no. 9, pp. 684-694, 2011.
108. H. Karlsson, T. Erkers, S. Nava, S. Ruhm, M. Westgren, and O. Ringdén, "Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro, " Clinical and Experimental Immunology, vol. 167, no. 3, pp. 543-555, 2012.
109. J. M. Lee, J. Jung, H.-J. Lee et al., "Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells, " International Immunopharmacology, vol. 13, no. 2, pp. 219-224, 2012.
110. S. Manochantr, Y. U-pratya, P. Kheolamai et al., "Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord, " Internal Medicine Journal, vol. 43, no. 4, pp. 430-439, 2013.
111. S. M. Melief, J. J. Zwaginga, W. E. Fibbe, and H. Roelofs, "Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts, " Stem Cells Translational Medicine, vol. 2, no. 6, pp. 455-463, 2013.
112. A. I. Caplan, "Why are MSCs therapeuticNew data: new insight, " Journal of Pathology, vol. 217, no. 2, pp. 318-324, 2009.
113. D. M. Choumerianou, G. Martimianaki, E. Stiakaki, L. Kalmanti, M. Kalmanti, and H. Dimitriou, "Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults, " Cytotherapy, vol. 12, no. 7, pp. 881-887, 2010.
114. O. Ringdén, T. Erkers, S. Nava et al., "Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease, " Stem Cells, vol. 31, no. 3, pp. 592-601, 2013.
115. A. Keating, "Mesenchymal stromal cells: new directions, " Cell Stem Cell, vol. 10, no. 6, pp. 709-716, 2012.
116. A. M. DiMarino, A. I. Caplan, andT. L. Bonfield, "Mesenchymal stem cells in tissue repair, " Frontiers in Immunology, vol. 4, article 201, 2013.
117. M. Sundin, O. Ringdén, B. Sundberg, S. Nava, C. Götherström, and K. Le Blanc, "No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients, " Haematologica, vol. 92, no. 9, pp. 1208-1215, 2007.
118. M. Battiwalla and P. Hematti, "Mesenchymal stem cells in hematopoietic stem cell transplantation, " Cytotherapy, vol. 11, no. 5, pp. 503-515, 2009.
119. T. Toubai, S. Paczesny, Y. Shono et al., "Mesenchymal stem cells for treatment and prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation, " Current Stem Cell Research &Therapy, vol. 4, no. 4, pp. 252-259, 2009.
120. J. L. Ferrara, J. E. Levine, P. Reddy, and E. Holler, "Graft-versushost disease, " The Lancet, vol. 373, no. 9674, pp. 1550-1561, 2009.
121. K. Le Blanc, I. Rasmusson, B. Sundberg et al., "Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, " The Lancet, vol. 363, no. 9419, pp. 1439-1441, 2004.
122. M. von Bonin, F. Stölzel, A. Goedecke et al., "Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium, " Bone Marrow Transplantation, vol. 43, no. 3, pp. 245-251, 2009.
123. I. Müller, S. Kordowich, C. Holzwarth et al., "Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation, " Blood Cells, Molecules, and Diseases, vol. 40, no. 1, pp. 25-32, 2008.
124. L. M. Ball, M. E. Bernardo, H. Roelofs et al., "Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graftversus-host disease, " British Journal ofHaematology, vol. 163, no. 4, pp. 501-509, 2013.
125. V. K. Prasad, K. G. Lucas, G. I. Kleiner et al., "Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (Prochymal (TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study, " Biology of Blood and Marrow Transplant, vol. 17, no. 4, pp. 534-541, 2011.
126. K. H. Wu, C. K. Chan, C. Tsai et al., "Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells, " Transplantation, vol. 91, no. 12, pp. 1412-1416, 2011.
127. J. Y. Weng, X. Du, S. X. Geng et al., "Mesenchymal stem cell as salvage treatment for refractory chronic GVHD, " Bone Marrow Transplantation, vol. 45, no. 12, pp. 1732-1740, 2010.
128. Y. Peng, X. Chen, Q. Liu et al., "Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10, " Leukemia, 2014.
129. U. Forslöw, O. Blennow, K. Leblanc et al., "Treatmentwithmesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation, " European Journal of Haematology, vol. 89, no. 3, pp. 220-227, 2012.
130. M. Remberger and O. Ringdén, "Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients, " International Journal of Hematology, vol. 96, no. 6, pp. 822-824, 2012.
131. M. Liu and Z. C. Han, "Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy, " Journal of Cellular and Molecular Medicine, vol. 12, no. 4, pp. 1155-1168, 2008.
132. S. Ghannam, C. Bouffi, F. Djouad, C. Jorgensen, and D. Noël, "Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications, " Stem Cell Research &Therapy, vol. 1, no. 1, article 2, 2010.
133. A. Dorronsoro, J. Fernández-Rueda, K. Fechter et al., "Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications, " Bone Marrow Research, vol. 2013, Article ID 203643, 8 pages, 2013.
134. D. Wang, H. Zhang, J. Liang et al., "Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience, " Cell Transplantation, vol. 22, no. 12, pp. 2267-2277, 2013.
135. D. Wang, X. Feng, L. Lu et al., "CD8 T cell/indoleamine 2, 3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus, " Arthritis & Rheumatology, vol. 66, no. 8, pp. 2234-2245, 2014.
136. D. Wang, J. Li, Y. Zhang et al., "Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study, " Arthritis Research andTherapy, vol. 16, no. 2, article R79, 2014.
137. T. G. Woodworth and D. E. Furst, "Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a doubleblind placebo-controlled trial to determine efficacy, " Arthritis Research andTherapy, vol. 16, no. 4, p. 113, 2014.
138. X. Li, D. Wang, J. Liang, H. Zhang, and L. Sun, "Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus, " Bone Marrow Transplantation, vol. 48, no. 4, pp. 544-550, 2013.
139. F. Schena, C. Gambini, A. Gregorio et al., "Interferon-dependent inhibition of B cell activation by bone marrowderived mesenchymal stem cells in a murine model of systemic lupus erythematosus, " Arthritis & Rheumatism, vol. 62, no. 9, pp. 2776-2786, 2010.
140. M. Youd, C. Blickarz, L. Woodworth et al., "Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease, " Clinical Experimental Immunology, vol. 161, no. 1, pp. 176-186, 2010.
141. R. R. Bhonde, P. Sheshadri, S. Sharma, and A. Kumar, "Making surrogate-cells from mesenchymal stromal cells: perspectives and future endeavors, "The International Journal of Biochemistry Biology, vol. 46, no. 1, pp. 90-102, 2014.
142. A. V. Vanikar, S. D. Dave, U. G. Thakkar, and H. L. Trivedi, "Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus, " Stem Cells International, vol. 2010, Article ID 582382, 5 pages, 2010.
143. J. Hu, X. Yu, Z. Wang et al., "Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus, " Endocrine Journal, vol. 60, no. 3, pp. 347-357, 2013.
144. F. Ezquer, M. Ezquer, D. Contador, M. Ricca, V. Simon, and P. Conget, "The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment, " Stem Cells, vol. 30, no. 8, pp. 1664-1674, 2012.
145. E. J. Bassi, P. M. M. Moraes-Vieira, C. S. R. Moreira-Sá et al., "Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes, " Diabetes, vol. 61, no. 10, pp. 2534-2545, 2012.
146. H. Wu, D. Wen, and R. I. Mahato, "Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model, " Molecular Therapy, vol. 21, no. 9, pp. 1778-1786, 2013.
147. S. Morando, T. Vigo, M. Esposito et al., "The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and centralmechanisms, " Stem Cell Research andTherapy, vol. 3, article 3, 2012.
148. E. Zappia, S. Casazza, E. Pedemonte et al., "Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy, " Blood, vol. 106, no. 5, pp. 1755-1761, 2005.
149. M. Rafei, P. M. Campeau, A. Aguilar-Mahecha et al., "Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner, " The Journal of Immunology, vol. 182, no. 10, pp. 5994-6002, 2009.
150. R. Liu, Z. Zhang, Z. Lu et al., "Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination, " Stem Cells and Development, vol. 22, no. 7, pp. 1053-1062, 2013.
151. J. D. Glenn, M. D. Smith, P. A. Calabresi, and K. A. Whartenby, "Mesenchymal stem cells differentially modulate effector CD8+ T cell subsets and exacerbate experimental autoimmune encephalomyelitis, " Stem Cells, vol. 32, no. 10, pp. 2744-2755, 2014.
152. A. Uccelli, M. Milanese, M. C. Principato et al., "Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis, " Molecular Medicine, vol. 18, no. 5, pp. 794-804, 2012.
153. C. Zhou, C. Zhang, R. Zhao, S. Chi, and P. Ge, "Humanmarrow stromal cells reduce microglial activation to protect motor neurons in a transgenic mouse model of amyotrophic lateral sclerosis, " Journal of Neuroinflammation, vol. 10, article 52, 2013.
154. D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al., "Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis, " Archives of Neurology, vol. 67, no. 10, pp. 1187-1194, 2010.
155. L. Mazzini, I. Ferrero, V. Luparello et al., "Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial, " Experimental Neurology, vol. 223, no. 1, pp. 229-237, 2010.
156. F. Djouad, V. Fritz, F. Apparailly et al., "Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor in collagen-induced arthritis, " Arthritis and Rheumatism, vol. 52, no. 5, pp. 1595-1603, 2005.
157. E. Schurgers, H. Kelchtermans, T. Mitera, L. Geboes, and P. Matthys, "Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis, " Arthritis Research and Therapy, vol. 12, article R31, 2010.
158. B. Chen, J. Hu, L. Liao et al., "Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6, " Clinical and Experimental Immunology, vol. 159, no. 3, pp. 292-302, 2010.
159. A. Papadopoulou, M. Yiangou, E. Athanasiou et al., "Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 71, no. 10, pp. 1733-1740, 2012.
160. Z. Zhang, Y. Ding, W. Li, B. Song, and R. Yang, "Interleukin-17A-or tumor necrosis factor-mediated increase in proliferation of T cells cocultured with synovium-derivedmesenchymal stemcells in rheumatoid arthritis, "Arthritis Research&Therapy, vol. 15, no. 5, article no. R169, 2013.
161. C. Sullivan, J. M. Murphy, M. D. Griffin et al., "Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis, " Arthritis Research and Therapy, vol. 14, article R167, 2012.
162. M. A. González, E. González-Rey, L. Rico, D. Büscher, and M. Delgado, "Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stemcells, "Arthritis&Rheumatism, vol. 60, no. 4, pp. 1006-1019, 2009.
163. M. Chen, W. Su, X. Lin et al., "Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collageninduced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation, " Arthritis and Rheumatism, vol. 65, no. 5, pp. 1181-1193, 2013.
164. O. Kehoe, A. Cartwright, and A. Askari, "Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritis, " Journal of Translational Medicine, vol. 12, article 157, 2014.
165. J. Liang, X. Li, H. Zhang et al., "Allogeneic mesenchymal stem cells transplantation in patients with refractory RA, " Clinical Rheumatology, vol. 31, no. 1, pp. 157-161, 2012.
166. L. Wang, X. Cong, G. Liu et al., "Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy, " Stem Cells and Development, vol. 22, no. 24, pp. 3192-3202, 2013.